Role of resistance testing during oral antiviral therapy of chronic hepatitis B

Current Hepatitis Reports

Volumn 11, Issue 2, 2012, Pages 55-64

  Devi, Uma ^a,b   Locarnini, Stephen ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b Infectious Diseases Unit   (Australia)

Author keywords

Antiviral agents; Genotypic resistance; Hepatitis B; Mutation; Phenotypic resistance; Viral resistance testing

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; CROSS RESISTANCE; DNA HYBRIDIZATION; DNA MICROARRAY; DNA SEQUENCE; DRUG POTENCY; DRUG SUBSTITUTION; ENZYME INHIBITION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; PYROSEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL GENE; VIREMIA; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84865789158     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-012-0132-8     Document Type: Article

References (83)

1. Clercq ED. Antiviral drugs in current clinical use. J Clin Virol. 2004;30:115-33.
2. Greene WC, Debyserb Z, Ikeda Y. Novel targets for HIV therapy. Antivir Res. 2008;80:251-65.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 10. 2011. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultescentGL.pdf. Accessed on January 20, 2012.
4. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-42.
5. Yuen M, Sablon E, Hui C, Yuan H, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785-91.
6. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomised controlled trial. Lancet. 1999;353:2195-9.
7. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-66.
8. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94.
9. Corzillius M, Muhlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antivir Ther. 2004;9:27-36.
10. Baxter J, Douglas M, Wentworth DN. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14: F83-93.
11. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000;5:41-8.
12. Wegner S, Wallace M, Aronson N, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis. 2004;38:723-30.
13. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havanatrial. AIDS. 2002;16:209-18.
14. Weinstein MC, Goldie S, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-50.
15. Fung S, Andreone P, Han S, Reddy RK, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol. 2005;43:937-43.
16. Hyung JY, Hussain M, Liu Y. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44:703-12.
17. Wong V,Wong G, Tse CH, et al. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci. 2011;57:221-31.
18. Chainuvati S, Cheng J, Hou JL, et al. Patterns of managing chronic hepatitis B treatment-related rug resistance: a survey of physicians in Mainland China, South Korea, Taiwan and Thailand. Hepatol Int. 2009;3:453-60.
19. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis. 2010;14:439-59.
20. Lee Y-S, Suh DJ, Lim Y-S, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385-91.
21. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172• mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48:88-98.
22. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother. 2007;51:2285-92.
23. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis. 2005;25 Suppl 1:9-19.
24. Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29-60.
25. Iloeje U, Yang H, Su J, Jen C, You S, Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-86.
26. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and intepretation. J Hepatol. 2006;44:593-606.
27. Domingo E. Quasispecies and the development of new antiviral strategies. Progr Drug Res. 2003;60:133-58.
28. Clavel F, Hance A. HIV drug resistance. N Engl J Med. 2004;350:1023-35.
29. Dienstag JL, Perrillo R, Schiff E, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657-61.
30. Dienstag JL, Schiff E, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-63.
31. Lai CL, Chien RN, Leung NW. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:241-4.
32. Lai CL, Dienstag JL, Schiff E. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687-96.
33. Papatheodoris G, Lampertico P, Manolakopolous S, Lok A. Incidence of heptocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348-56. This meta-analysis showed an increased risk of HCC in patients who failed to maintain virological remission. Furthermore, comparing antiviral naive patients to those with LMV resistance, whether or not cirrhosis was present, the rate of HCC was higher if there was LMV resistance as well.
34. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-31.
35. Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol. 2007;22:1078-85.
36. Delaney WET, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother. 2001;12:1-35.
37. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-608.
38. Ogata N, Fujii K, Takigawa S. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol. 1999;59:270-6.
39. Delaney W, Yang H, Westland CE, Das K, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833-43.
40. Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology. 1995;21:14-8.
41. Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology. 2002;299:88-99.
42. Kamili Samili SV, ThompsonG, Campbell K,Walker CM, Locarnini S, Krawczynski K. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology. 2009;49:1483-92.
43. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of nextgeneration nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther. 2005;10:625-33.
44. Lai C-L, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576-88.
45. Liaw YF, Gane E, Leung N, et al. 2-year globe trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-95.
46. Dando T, Plosker G. Adefovir dipivoxil. A review of its use in chronic HBVAdis drug evaluation. Drugs. 2003;63:2215-34.
47. Hadziyannis S, Tassopoulos N, Heathcote J, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-51.
48. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125:292-7.
49. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247-9
50. Snow-Lampert A, Chappell B, Curtis M. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53:763-73.
51. Lin P-F, Nowicka-Sans B, Terry B, et al. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother. 2008;52:1759-67.
52. McMahon M, Benjamin B, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614-21.
53. Levine S, Hernandez D, Yamanak G, Zhang S, Rose RE, et al. Efficacies of entecavir against lamivudine-resistant hepatitis b virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002;46:2525-32.
54. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Morris S, Wong D, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139:1218-29.
55. Tenney D, Rose R, Baldick C, Pokornowski K, Eggers B, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-14.
56. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004;48:3498-507.
57. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve J, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. 2007;46:531-8.
58. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, et al. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther. 2010;15:1185-90.
59. Brunelle M, Jacquard A, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve J, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41:1391-8.
60. Chang T, Lai CNEJM. Hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;355:322-3.
61. Kim H, Han K, Ahn S, Kim E, Chang H, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther. 2005;10:441-9.
62. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol. 2006;44:1094-7.
63. Jang H, Cho M, Heo J, Kim H, Jun H, Shin W, et al. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol. 2004;42:4181-8.
64. Marrgeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275-85.
65. Solmone M, Vincenti D, Prosperi M, Bruselles A, et al. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drugnaive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. 2009;83:1718-26.
66. Zoulim F. In-vitro models for studying hepatitis B virus drug resistance. Liver Dis. 2006;26:171-80.
67. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology. 2002;36:710-22.
68. Durantel D, Carrouee-Durantel S,Werle-Lapostolle B, Brunelle M, Pichoud C, Trepo C, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology. 2004;40:855-64.
69. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol. 2002;40:3729-34.
70. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antivir Res. 2007;75:64-74.
71. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-65.
72. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679-93.
73. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther. 2008;13:381-8.
74. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS. 2002;16:131-3.
75. Besisik F, Karaca C, Akyuz F, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. Hepatology. 2003;38:506.
76. Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, et al. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains. J Gastroenterol Hepatol. 2010;25:745-9.
77. Alvarado-Esquivel C, Carrera-Gracia MA, Conde-González CJ, et al. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother. 2006;57:221-3.
78. Pol S, Sogni P. Treatment of chronic hepatitis B: adherence and safety. Gastroenterol Clin Biol. 2010;34(Supple 2):S142-8.
79. Chotiyaputta W, Peterson C, Ditah F, Goodwin D, Lok A. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol. 2010;54:12-8.
80. Lok A, McMahon B. Chronic hepatitis B: update 2009. AASLD Practice Guidelines. Hepatology. 2009:1-36.
81. Fung S, Chae HB, Fontana R. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;43:283-90.
82. Florian B, Mahnaz A, Francesco N. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. Swiss Med Wkly. 2010;140:154-9.
83. Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008;48:714-20.